Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
about
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalCancer vaccines and T cell therapyDeveloping strategies in the immunotherapy of leukemiasEvaluation of current cancer immunotherapy: hemato-oncologyActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsA new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemiaImpaired B cell immunity in acute myeloid leukemia patients after chemotherapy.Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotWilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.Haematological malignancies: at the forefront of immunotherapeutic innovation.Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesThe role of peptide and DNA vaccines in myeloid leukemia immunotherapyPersistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.STAT3: the "Achilles" heel for AML?Understanding CD8+ T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope.DNA fusion vaccines enter the clinic.Clinical peptide vaccination trials for leukemia patients.Vaccination strategies in lymphomas and leukaemias: recent progress.Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.Current strategies in immunotherapy for acute myeloid leukemia.Peptide vaccines for hematological malignancies: a missed promise?Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge.Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.Update on antigen-specific immunotherapy of acute myeloid leukemia.Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.Life after transplant: are we becoming high maintenance in AML?Cancer Vaccines: A Brief Overview.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Differential ion mobility spectrometry coupled to tandem mass spectrometry enables targeted leukemia antigen detection.
P2860
Q26744536-F5AEE736-E82A-424F-A8DC-1655A7A57938Q26995638-58FBEB50-D126-441E-B0C4-F4F7569FBA67Q26996310-E2DDB96A-B858-493E-8598-0BC81DF4A871Q27006179-A5307854-D211-4078-8243-BCFCAA782A68Q27026836-8450DF6C-71E3-4B7F-AA28-B8FE5FB480EEQ33849643-FB8D4068-613B-4212-A92B-14E0EAA13934Q33892358-6EC01208-A82D-4304-A278-82D015D7B3DCQ33954123-B7EBED6C-4F05-4DCD-8302-48EA6B7E2185Q34180369-42F710A1-1C60-4E67-9B30-01D2F979D2CBQ34617770-AD7F3D02-ABFE-4F56-8B80-A83EA914644FQ34980976-AB92F07C-EDEE-4E80-8194-06DDEC7C0D03Q35240847-503E62EC-0769-4867-B514-9EC88FD816F0Q35880618-953F692B-CD02-4CB9-AAC7-5437F0C6C7A4Q35889240-FCB2F501-CB05-4C48-99D9-9EAE22300BD5Q35931271-D56D3D36-991E-4143-B651-4C205D62A447Q36194241-227DE2F5-B0F1-40F0-A9B1-998C764EF60BQ36198150-7C5B34CD-7AC2-4B00-A251-DE0193AF63F6Q36608571-4FE12676-254F-4837-A4AB-0B2926076429Q36745336-B1C70873-5251-4BBF-BD32-E4C8E02D8D1AQ37000485-EDB7DB95-36E5-46BF-8A5E-A6C980B6F508Q37429669-8F01B386-2E08-480A-8842-FAEC319068CBQ37739362-0A7E71B1-E84D-49F7-BA6A-9D0811FF4658Q37885288-2BEE508A-624C-41E9-B56D-1B2F2E4300E0Q37892584-BE80C18C-2943-4245-B09C-18CA32D8F7CBQ37929157-FA528710-9294-4100-9404-B1C36F492C14Q38003477-1C715DC3-C52F-419A-B691-D6C16968040AQ38068967-0FB72B59-A131-4896-AC22-C9AAB803CF8BQ38176546-C9853876-51AD-48DA-8887-2376B9643A05Q38176625-BF7FD63C-DD32-4334-9A97-3118F379972CQ38195065-85727856-C2A3-49A6-928B-C8A23A73B880Q38208388-13C4E32E-41C5-4623-97CB-4255CF2EB930Q38318616-598575F3-36D5-46A5-AC8C-D1205D8941BEQ38362636-F8A907C2-F59F-4AC8-9411-04AC4F1843F0Q38432103-51B3FA74-F03F-4ABA-B47A-F6407898C58FQ38705015-69A27A0A-878B-41C2-B909-03BBFFC76F07Q38714821-92211C4B-C591-4A76-89D2-3DC2553F4ED8Q38801124-A7F13CBA-CC62-4FDB-8C96-C3FBCC190870Q38807846-193AB648-0B8A-477B-979D-5C7DF0B33C3CQ38843235-67E23720-C0BE-4962-8A92-5CEC211C42F4Q38960204-0E2ABC3F-A52E-47BE-9380-7ACE231B89D1
P2860
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@ast
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@en
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@nl
type
label
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@ast
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@en
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@nl
prefLabel
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@ast
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@en
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies.
@nl
P2093
P2860
P1433
P1476
Repeated PR1 and WT1 peptide v ...... cells in myeloid malignancies
@en
P2093
A John Barrett
Behnam Jafarpour
Bipin N Savani
Carol Boss
Katayoun Rezvani
Laura Musse
Rhoda Eniafe
Robert Q Le
Roger Kurlander
P2860
P304
P356
10.3324/HAEMATOL.2010.031674
P577
2010-12-06T00:00:00Z